Status:
COMPLETED
3D Visualization System for Vitreoretinal Diseases in Highly Myopic Eyes
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Alcon Research
Conditions:
Patients With Highly Myopic Eyes
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
To investigate the surgical outcomes and intraoperative parameters evaluation of 3D visualization system for vitreoretinal diseases in highly myopic eyes
Detailed Description
The investigators aimed to compare the safety and efficacy of NGENUITY® 3D Visualization System (Alcon, TX, USA) in vitreoretinal surgery of highly myopic patients with standard binocular microscope p...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Highly myopic patients (axial length ≥ 26mm, no upper limit)
- Patient with vitreoretinal pathology that require vitrectomy who had not received previous ICG or BBG-assisted membrane peeling
- Patient aged ≥ 20 years
- Exclusion criteria:
- Patient who had previous ICG or BBG-assisted membrane peeling
- Patient who received combined vitrectomy and trabeculectomy
- Patient with endophthalmitis or intraocular foreign body
Exclusion
Key Trial Info
Start Date :
October 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05367193
Start Date
October 7 2022
End Date
March 16 2023
Last Update
June 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100